Teleangiectasia hereditaria haemorrhagica –Osler-Weber-Rendu syndrome. Case study and treatment experience

Česká verzia

Authors: Z. Adam ¹; G. Chlupová ²; A. Neumann ³; B. Jakubcová ³; J. Simonides ⁴; Z. Adamová ⁵; J. König ⁶; P. Krupa ⁷; P. Szturz ¹; L. Pour ¹; M. Krejčí ¹; R. Hájek ¹; Z. Král ¹; J. Mayer ¹
Authors place of work: Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc. ¹; Oddělení klinické hematologie FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc. ²; Radiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Vlastimil A. Válek, CSc., MBA ³; Hematologicko-transfuzní oddělení Nemocnice Znojmo, p. o., Znojmo, přednosta prim. MUDr. Jan Simonides ⁴; Ambulance pro děti a dorost Brno, Obilní trh ⁵; Oddělení ORL FN Brno, pracoviště Bohunice, přednosta prim. MUDr. Aleš Trnka ⁶; Oddělení zobrazovacích metod SurGal Clinic, s. r. o., Brno, přednosta prim. MUDr. Jan Křístek, Ph. D. ⁷
Published in the journal: Vnitř Lék 2012; 58(6): 477-489
Category: Case Reports

Summary

Hereditary haemorrhagic telangiectasy is an inborn disease with autosomal dominant transmission. Nose bleeding usually occurs during the 2nd decade of life as the first sign of the disease. Later, during the 3rd or 4th decade of life, typical subtle, pinhead-sized (1–2 mm in diameter) vascular arteriovenous malformations occur. These are usually found on the oral mucosa and in the stomach and small intestine. During later stages of the disease, nose as well as gastrointestinal bleeding causes severe anaemia requiring transfusions. Advanced stages of hereditary hemorrhagic telangiectasy are associated with a development of ateriovenous vascular malformations in the liver, lungs and possibly the brain. Vascular ateriovenous malformations in the liver cause hyperkinetic circulation that may lead to heart failure. Blood within the pulmonary ateriovenous malformations bypasses filtration in the pulmonary capillary circulation and thus infected microtrombi may pass from the inferior vena cava to, for example, the brain. At first, local treatment – stopping epistaxis – is used. Symptomatic embolisation treatment and, sometimes, liver transplantation are used in advanced forms of the disease with anaemisation, despite iron substitution, and clinically significant ateriovenous malformations. Angiogenesis-inhibiting substances have been shown effective in patients with an advanced disease. Older clinical studies confirmed benefits of combined oestrogen-progesterone treatment, later also treatment with raloxifene or antioestrogens. Many post-2000 publications showed thalidomide and bevacizumab to be effective in this indication. Treatment with bevacizumab has led not only to increased haemoglobin concentrations but, through regression of ateriovenous malformations, provided control of hyperkinetic circulation. Discussion section provides an overview of treatment modalities. The main text describes a case of a 56 years old female patient with hypochromic anaemia despite maximum oral iron substitution. The patient lost blood through repeated epistaxes as well as continuous mild bleeding into gastrointestinal tract. The patient also had confirmed large ateriovenous malformations in the liver. Interferon alpha was used as the first line of treatment. The patient unexpectedly developed fast and pronounced myelosuppression. The number of neutrophils fell down from 1.15 x 10⁹/l to 0.6 × 10⁹/l as soon as after 3 injections of interferon alpha at a starting dose of 1.5 million units 3 times a week. Therefore, interferon alpha was discontinued. Blood count returned to normal following interferon discontinuation. The patient was started on thalidomide in December 2011. The patient reported lower incidence of epistaxes and smaller blood loss than before treatment as soon as during the first month of therapy. Regular administration of thalidomide reduced intensity and frequency of epistaxes in this patient.

Key words:
hereditary haemorrhagic telangiectasia – syndrom Osler-Weber-Rendu – haemangiomas – arteriovenous malformations – epistaxis – anaemia – estrogens – antiestrogens – raloxifen – thalidomide – bevacizumab – interferon α

Zdroje

1. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333: 918–924.

2. Ernest J, Krampolová Poláčková V, Charvát F. Oční komplikace po embolizaci v povodí arteria carotis interna – kazuistika. Cesk Slov Oftalmol 2008; 64: 202–206.

3. Takác M, Koval S, Klimcík J. Hereditární hemoragická telangiektasie a vznik artriovenózní fistuly po 24 letech. Vnitř Lék 1997; 43: 599–601.

4. Krahulec B, Jergus P, Bátovský M et al. Telangiektázie v žaludku u pacienta s Oslerovou chorobou. Bratisl Lek Listy 1988; 89: 11–13.

5. Štastný B, Kroslák M. Chirurgická léčba epistaxe u pacienta s morbus Osler-Rendu-Weber. Česk Otolaryngol 1981; 30: 53–56.

6. Izák M. Sturge-Weber-Krabbe syndrom. Česk Oftalmol 1971; 27: 267–272.

7. Chvojka J. Zástava epistaxe u pacienta s morbus Osler-Rendu-Weber. Česk Otolaryngol 1967; 16: 211–214.

8. Faughnan ME, Palda VA, Garcia-Tsao G et al. HHT Foundation International – Guidelines Working Group. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48: 73–87.

9. Trerotola SO, Pyeritz RE, White RI Jr et al. HHT Foundation. HHT Centers. 2009 Treatment guidelines for hereditary hemorrhagic telangiectasia. J Vasc Interv Radiol 2010; 21: 179.

10. Plauchu H, de Chadarévian JP, Bideau A et al. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32: 291–297.

11. Shovlin CL, Guttmacher AE, Buscarini E et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66–67.

12. Haitjema T, Westermann CJJ, Overtoom TT et al. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu-disease): new insights in pathogenesis, complications, and treatment. Arch Intern Med 1996; 156: 714–719.

13. Reilly PJ, Nostrant TT. Clinical manifestations of hereditary hemorrhagic telangiectasia. Am J Gastroenterol 1984; 79: 363–367.

14. McDonald JE, Miller FJ, Hallam SE et al. Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred. Am J Med Genet 2000; 93: 320–327.

15. Olitsky SE. Hereditary hemorrhagic telangiectasia: diagnosis and management. Am Fam Physician 2010; 82: 785–790.

16. Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24: 203–219.

17. Zarrabeitia R, Albiñana V, Salcedo M et al. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT). Curr Vasc Pharmacol 2010; 8: 473–481.

18. McDonald J, Bayrak-Toydemir P. Hereditary hemorrhagic telangiectasia. Haematologica 2005; 90: 728–732.

19. Folz BJ, Zoll B, Alfke H et al. Manifestations of hereditary hemorrhagic telangiectasia in children and adolescents. Eur Arch Otorhinolaryngol 2006; 263: 53–61.

20. McAllister KA, Grogg KM, Johnson DW et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8: 345–351.

21. Johnson DW, Berg JN, Baldwin MA et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996; 13: 189–195.

22. Cole SG, Begbie ME, Wallace GM et al. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005; 42: 577–582.

23. Sadick H, Riedel F, Naim R et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005; 90: 818–828.

24. Pardali E, Goumans MJ, ten Dijke P. Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol 2010; 20: 556–567.

25. Castonguay R, Werner ED, Matthews RG et al. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem 2011; 286: 30034–30046.

26. Dupuis-Girod S, Bailly S, Plauchu H. Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J Thromb Haemost 2010; 8: 1447–1456.

27. Matsubara S, Mandzia JL, ter Brugge K et al. Angiographic and clinical characteristics of patients with cerebral arteriovenous malformations associated with hereditary hemorrhagic telangiectasia. AJNR Am J Neuroradiol 2000; 21: 1016–1020.

28. Drouet A, Le Moigne F, Donat A et al. Brain abscess as the first clinical manifestation of isolated pulmonary arteriovenous malformation without Rendu-Osler disease. Rev Neurol (Paris) 2011; 167: 29–34.

29. Shovlin C, Bamford K, Wray D. Post-NICE 2008: Antibiotic prophylaxis prior to dental procedures for patients with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia. Br Dent J 2008; 205: 531–533.

30. Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54: 714–729.

31. Berg AM, Amirbekian S, Mojibian H et al. Hemothorax due to rupture of pulmonary arteriovenous malformation: an interventional emergency. Chest 2010; 137: 705–707.

32. Reichenberger F, Wehner LE, Breithecker A et al. Pulmonary hypertension in hereditary haemorrhagic teleangiectasia. Pneumologie 2009; 63: 669–674.

33. Chang SA, Jang SY, Ki CS et al. Successful bosentan therapy for pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia. Heart Vessels 2011; 26: 231–234.

34. Ruygrok M, Combs B, Campbell J et al. Heart failure, aneurysms and telangiectases, oh my! Am J Med 2011; 124: 605–607.

35. Koscielny A, Willinek WA, Hirner A et al. Treatment of high output cardiac failure by flow-adapted hepatic artery banding (FHAB) in patients with hereditary hemorrhagic telangiectasia. J Gastrointest Surg 2008; 12: 872–876.

36. Khalid SK, Pershbacher J, Makan M et al. Worsening of nose bleeding heralds high cardiac output state in hereditary hemorrhagic telangiectasia. Am J Med 2009; 122: 779. e1–e9.

37. Garcia-Tsao G. Liver involvement in hereditary hemorrhagic telangiectasia (HHT). J Hepatol 2007; 46: 499–507.

38. Garcia-Tsao G, Korzenik JR, Young L et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2000; 343: 931–936.

39. Al-Saleh S, John PR, Letarte M et al. Symptomatic liver involvement in neonatal hereditary hemorrhagic telangiectasia. Pediatrics 2011; 127: e1615–e1620.

40. Buscarini E, Leandro G, Conte D et al. Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia. Dig Dis Sci 2011; 56: 2166–2178.

41. Henrion J, Deltenre P, Peny MO et al. Fatal hypoxic hepatitis in a patient with hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber’s disease). Acta Gastroenterol Belg 2010; 73: 61–64.

42. Khalid SK, Garcia-Tsao G. Hepatic vascular malformations in hereditary hemorrhagic telangiectasia. Semin Liver Dis 2008; 28: 247–258.

43. Sabbà C, Pompili M. Review article: the hepatic manifestations of hereditary haemorrhagic telangiectasia. Aliment Pharmacol Ther 2008; 28: 523–533.

44. Scelzo C, Greco S, Bonanni L et al. The role of liver transplantation in the treatment of hereditary hemorrhagic telangiectasia: a short literature review. Transplant Proc 2007; 39: 2045–2047.

45. Song X, Chen HQ, Chen YX et al. Individualized management of hepatic diseases in hereditary hemorrhagic telangiectasia. Am Surg 2011; 77: 281–285.

46. Lee M, Sze DY, Bonham CA et al. Hepatic arteriovenous malformations from hereditary hemorrhagic telangiectasia: treatment with liver transplantation. Dig Dis Sci 2010; 55: 3059–3062.

47. Lerut J, Orlando G, Adam R et al. Liver transplantation for hereditary hemorrhagic telangiectasia: report of the European liver transplant registry. Ann Surg 2006; 244: 854–864.

48. Chowdhry SA, Ponsky DC, Hsu DP. Treatment of a nasal vascular malformation in a patient with Osler-Weber-Rendu syndrome via percutaneous N-butyl 2-cyanoacrylate embolization: case report and review of the literature. J Otolaryngol Head Neck Surg 2011; 40: E11–E14.

49. Harvey RJ, Kanagalingam J, Lund VJ. The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Am J Rhinol 2008; 22: 182–187.

50. Lund VJ, Howard DJ. Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic telangiectasia. J Laryngol Otol 1997; 111: 30–33.

51. Richmon JD, Tian Y, Husseman J et al. Use of a sprayed fibrin hemostatic sealant after laser therapy for hereditary hemorrhagic telangiectasia epistaxis. Am J Rhinol 2007; 21: 187–191.

52. Flessa HC, Glueck HI. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): management of epistaxis in nine patients using systemic hormone therapy. Arch Otolaryngol 1977; 103: 148–151.

53. van Cutsem E, Rutgeerts P, Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 1990; 335: 953–955.

54. Albiñana V, Bernabeu-Herrero ME, Zarrabeitia R et al. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells. Thromb Haemost 2010; 103(3): 525–534.

55. Yaniv E, Preis M, Hadar T et al. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope 2009; 119: 284–288.

56. Yaniv E, Preis M, Shevro J et al. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia – a long-term clinical trial. Rhinology 2011; 49: 214–216.

57. Zheng JW, Zhou Q, Yang XJ et al. Anti-estrogenic agents might be more favorable option for treatment of hereditary hemorrhagic telangiectasia. Med Hypotheses 2009; 72: 230–231.

58. Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol 2007; 39: 1489–1499.

59. D’Amato RJ, Loughnan MS, Flynn E et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994; 91: 4082–4085.

60. Therapontos C, Erskine L, Gardner ER et al. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci 2009; 106: 8573–8578.

61. Lebrin F, Srun S, Raymond K et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16: 420–428.

62. Nau JY. Thalidomide: new therapeutic indications? Rev Med Suisse 2010; 6: 846–847.

63. Akhurst RJ. Taking thalidomide out of rehab. Nat Med 2010; 16: 370–372.

64. Penaloza A, Vekemans MC, Lambert C et al. Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. Blood Coagul Fibrinolysis 2011; 22: 616–618.

65. Alberto SF, Felix J, de Deus J. Thalidomide for the treatment of severe intestinal bleeding. Endoscopy 2008; 40: 788–789.

66. Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007; 13: 5979–5984.

67. Bauditz J, Schachschal G, Wedel S et al. Thalidomide for treatment of severe intestinal bleeding. Gut 2004; 53: 609–612.

68. Bauditz J. Angiogenesis inhibitors for treatment of angiodysplasia-related gastrointestinal bleeding. Dtsch Med Wochenschr 2009; 134: 1893–1896.

69. Dabak V, Kuriakose P, Kamboj G et al. A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias. Dig Dis Sci 2008; 53: 1632–1635.

70. Chen CH, Hsu HH, Hu RH et al. Long term therapy with thalidomide in hereditary hemorrhagic telangiectasia: case report and literature review. J Clin Pharmacol 2011. In press.

71. Kamalaporn P, Saravanan R, Cirocco M et al. Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series. Eur J Gastroenterol Hepatol 2009; 21: 1347–1350.

72. Kurstin R. Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease. Oncology 2002; 16: 21–24.

73. Pérez-Encinas M, Rabuñal Martínez MJ, Bello López JL. Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia? Haematologica 2002; 87: ELT34.

74. Sardi I, Sanzo M, Giordano F et al. Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel-Lindau disease. Pediatr Blood Cancer 2009; 53: 464–467.

75. Frei-Jones M, McKinstry RC, Perry A et al. Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. J Neurosurg Pediatr 2008; 2: 125–129.

76. Piribauer M, Czech T, Dieckmann K et al. Stabilization of a progressive hemangioblastoma under treatment with thalidomide. J Neurooncol 2004; 66: 295–299.

77. Jarvi K, Roebuck DJ, Sebire NJ et al. Successful treatment of extensive infantile hemangiomatosis of the small bowel in a 3-month-old with thalidomide and somatostatin analog. J Pediatr Gastroenterol Nutr 2008; 46: 593–597.

78. Tan DS, Evanson J, Plowman PN et al. Post-radiation inflammatory reaction controlled with thalidomide and rofecoxib. Clin Oncol (R Coll Radiol) 2004; 16: 585–586.

79. Bölke E, Gripp S, Peiper M et al. Multifocal epithelioid hemangioendothelioma: case report of a clinical chamaeleon. Eur J Med Res 2006; 11: 462–466.

80. Mascarenhas RC, Sanghvi AN, Friedlander L et al. Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. Oncology 2004; 67: 471–475.

81. Adam Z, Pour L, Krejčí M et al. Úspěšná léčba angiomatózy thalidomidem a interferonem α. Popis 5 případů a přehled léčby angiomatózy a proliferujících hemangiomů. Vnitř Lék 2010; 56: 810–823.

82. Bowcock SJ, Patrick HE. Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias? Br J Haematol 2009; 146: 220–222.

83. Chen S 4th, Karnezis T, Davidson TM. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011; 121: 644–646.

84. Karnezis TT, Davidson TM. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia--associated epistaxis. Laryngoscope 2011; 121: 636–638.

85. Rohrmeier C, Sachs HG, Kuehnel TS. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Otorhinolaryngol 2012; 269: 531–536.

86. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 360: 2143–2144.

87. Brinkerhoff BT, Poetker DM, Choong NW. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2011; 364: 688–689.

88. Cruikshank RP, Chern BW. Bevacizumab and hereditary haemorrhagic telangiectasia. Med J Aust 2011; 194: 324–325.

89. Davidson TM, Olitsky SE, Wei JL. Hereditary hemorrhagic telangiectasia/avastin. Laryngoscope 2010; 120: 432–435.

90. Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006; 85: 631–632.

91. Fodstad P, Dheyauldeen S, Rinde M et al. Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia. Ann Hematol 2011; 90: 611–612.

92. Oosting S, Nagengast W, de Vries E. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 361: 931–932.

93. Simonds J, Miller F, Mandel J et al. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009; 119: 988–992.

94. Suppressa P, Liso A, Sabbà C. Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia. Br J Haematol 2011; 152: 365.

95. Mitchell A, Adams LA, MacQuillan G et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 2008; 14: 210–213.

96. Buscarini E, Manfredi G, Zambelli A. Bevacizumab to treat complicated liver vascular malformations in hereditary hemorrhagic telangiectasia: a word of caution. Liver Transpl 2008; 14: 1685–1686.

97. Amanzada A, Töppler GJ, Cameron S et al. A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab. Case Rep Oncol 2010; 3: 463–470.

98. Kline RM, Buck LM. Bevacizumab treatment in multifocal lymphangioendotheliomatosis with thrombocytopenia. Pediatr Blood Cancer 2009; 52: 534–536.

99. Lindner DJ. Interferons as antiangiogenic agents. Curr Oncol Rep 2002; 4: 510–514.

100. Wheatley-Price P, Shovlin C, Chao D. Interferon for metastatic renal cell cancer causing regression of hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 2005; 39: 344–345.

101. Massoud OI, Youssef WI, Mullen KD. Resolution of hereditary hemorrhagic telangiectasia and anemia with prolonged alpha-interferon therapy for chronic hepatitis C. J Clin Gastroenterol 2004; 38: 377–379.

102. Faughnan ME, Granton JT, Young LH. The pulmonary vascular complications of hereditary haemorrhagic telangiectasia. Eur Respir J 2009; 33: 1186–1194.

103. Jaskolka J, Wu L, Chan RP et al. Imaging of hereditary hemorrhagic telangiectasia. AJR Am J Roentgenol 2004; 183: 307–314.

104. Grand’Maison A. Hereditary hemorrhagic telangiectasia. CMAJ 2009; 180: 833–835.